Lovastatin Extended-Release Tablets and Mavyret

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Glecaprevir may significantly increase the blood levels of lovastatin. This can increase the risk of side effects such as liver damage and a rare but serious condition called rhabdomyolysis that involves the breakdown of skeletal muscle tissue. In some cases, rhabdomyolysis can cause kidney damage and even death. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need to stop taking lovastatin while you are being treated with glecaprevir. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness during treatment with lovastatin or similar medications, especially if these symptoms are accompanied by fever or dark colored urine. You should also seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with glecaprevir-pibrentasvir may significantly increase the plasma concentrations of lovastatin and its active metabolites. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake of the statins and their metabolites by glecaprevir and pibrentasvir. Inhibition of CYP450 3A4-mediated metabolism may also contribute, as glecaprevir and pibrentasvir are weak inhibitors of the isoenzyme. When lovastatin 10 mg once daily was administered with glecaprevir-pibrentasvir 300 mg-120 mg once daily to 12 study subjects, lovastatin Cmax was not affected and AUC increased by just 1.7-fold, but the Cmax and AUC of the active metabolite lovastatin acid increased by approximately 5.7- and 4.1-fold, respectively. High levels of HMG-CoA reductase inhibitory activity in plasma may be associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.

MANAGEMENT: Concomitant use of lovastatin or red yeast rice (which contains lovastatin) with glecaprevir-pibrentasvir is not recommended. Other statins may be used with glecaprevir-pibrentasvir, but a dosage reduction may be required.

Lovastatin Extended-Release Tablets

Generic Name: lovastatin

Brand name: Altoprev, Mevacor, Altocor

Synonyms: Lovastatin

What is Lovastatin Extended-Release Tablets?

Mavyret

Generic Name: glecaprevir / pibrentasvir

Brand name: Mavyret

Synonyms: n.a.

What is Mavyret?